Becton, Dickinson and Company

Becton, Dickinson and Company

BDXB

$48.16

Updated: 24/09/2026, 11:05:57

Market Cap
$13.69B
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US

No historical data available

Company Profile

Becton, Dickinson and Company (BD) is a leading global medical technology enterprise. It designs, produces, and distributes a comprehensive portfolio of medical supplies, devices, laboratory instruments, and diagnostic solutions. Its diverse customer base spans healthcare institutions, medical professionals, life science researchers, clinical laboratories, the pharmaceutical industry, and consumers worldwide. The BD Medical segment concentrates on medication management and patient care. This division delivers a broad spectrum of products, including advanced IV and catheter systems (e.g., peripheral, central, dialysis), vascular access tools, and a variety of syringes and needles for general injection, anesthesia, and diabetes care. It also provides comprehensive solutions for medication preparation and administration, such as infusion therapy systems, automated dispensing units, and inventory tracking software, along with specialized prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostics and research. It supplies essential products for specimen and blood collection, along with advanced diagnostic systems covering automated blood and tuberculosis culturing, molecular testing, microorganism identification, drug susceptibility analysis, and liquid-based cytology. Furthermore, this segment provides rapid diagnostic assays, microbiology automation tools, and plated media. For cellular research and specialized clinical diagnostics, it offers fluorescence-activated cell sorters and analyzers, antibodies, reagent kits, and solutions for single-cell gene expression, oncology, immunology, and transplantation monitoring. BD Interventional provides a comprehensive portfolio for surgical and specialized interventional procedures. This encompasses products for hernia and soft tissue repair, a variety of biological and bioresorbable grafts, and biosurgery solutions. The segment also offers tools for surgical infection prevention, surgical and laparoscopic instrumentation, products for peripheral vascular intervention, and essential urology and critical care items. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

USD
NYSE
CEO: Thomas E. Polen Jr.
Employees: 77,000
https://www.bd.com
Asset Summaries
Latest generated summaries for BDXB

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for BDXB.
Share price
$48.16
Market cap
$13.69B
Exchange
NYSE
Currency
USD
CEO
Thomas E. Polen Jr.
Employees
77,000
IPO date
21/05/2020
Beta
0.564743
Last dividend
$0.00
Day range
$47.65 – $48.82
52-week range
$45.85 – $52.52
1-day performance
1.39%
1-year performance
5.04%
Current drawdown (1Y)
-8.30%
CIK
0000010795
CUSIP
075887406
ISIN
US0758874061
Created
07/12/2025, 02:57:47
Last update
24/09/2026, 11:05:57

Track Becton, Dickinson and Company with an AI analyst

See which prediction-market events move BDXB, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BDXB from your Railway `news_articles` table.

No news found for this symbol.